372 related articles for article (PubMed ID: 26617778)
41. Neoadjuvant conformal chemoradiation with induction chemotherapy for rectal adenocarcinoma. A prospective observational study.
Fekete Z; Muntean AS; Hica Ş; Rancea A; Resiga L; Csutak C; Todor N; Nagy VM
J Gastrointestin Liver Dis; 2014 Jun; 23(2):171-8. PubMed ID: 24949609
[TBL] [Abstract][Full Text] [Related]
42. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.
Suárez J; Vera R; Balén E; Gómez M; Arias F; Lera JM; Herrera J; Zazpe C
Colorectal Dis; 2008 Jul; 10(6):563-8. PubMed ID: 18070184
[TBL] [Abstract][Full Text] [Related]
43. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer.
Mace AG; Gantt GA; Skacel M; Pai R; Hammel JP; Kalady MF
Dis Colon Rectum; 2013 Nov; 56(11):1217-27. PubMed ID: 24104995
[TBL] [Abstract][Full Text] [Related]
44. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
[TBL] [Abstract][Full Text] [Related]
45. Is Chemotherapy or Radiation Therapy in Addition to Surgery Beneficial for Locally Advanced Rectal Cancer in the Elderly? A National Cancer Data Base (NCDB) Study.
Bergquist JR; Thiels CA; Shubert CR; Habermann EB; Hayman AV; Zielinski MD; Mathis KL
World J Surg; 2016 Feb; 40(2):447-55. PubMed ID: 26566779
[TBL] [Abstract][Full Text] [Related]
46. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy--implications for induction chemotherapy?
Yu SK; Tait D; Chau I; Brown G
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):505-11. PubMed ID: 24074924
[TBL] [Abstract][Full Text] [Related]
47. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
48. NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival.
Voboril R; Rychterova V; Voborilova J; Kubecova M; Fanta J; Dvorak J
Neoplasma; 2016; 63(3):462-70. PubMed ID: 26952512
[TBL] [Abstract][Full Text] [Related]
49. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
50. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy.
Ahn DH; Wu C; Wei L; Williams TM; Wuthrick E; Abdel-Misih S; Harzman A; Husain S; Schmidt C; Goldberg RM; Bekaii-Saab T
Am J Clin Oncol; 2017 Dec; 40(6):531-534. PubMed ID: 25723741
[TBL] [Abstract][Full Text] [Related]
51. Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer.
Araujo-Mino EP; Patt YZ; Murray-Krezan C; Hanson JA; Bansal P; Liem BJ; Rajput A; Fekrazad MH; Heywood G; Lee FC
Oncologist; 2018 Jan; 23(1):2-e5. PubMed ID: 29158365
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
[TBL] [Abstract][Full Text] [Related]
53. Morphological aspects of the hepatic response to neoadjuvant therapy.
Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
[TBL] [Abstract][Full Text] [Related]
54. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer.
Huh JW; Lee JH; Kim HR
Ann Surg; 2014 Mar; 259(3):508-15. PubMed ID: 23787217
[TBL] [Abstract][Full Text] [Related]
55. Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.
Bisschop C; van Dijk TH; Beukema JC; Jansen RLH; Gelderblom H; de Jong KP; Rutten HJT; van de Velde CJH; Wiggers T; Havenga K; Hospers GAP
Ann Surg Oncol; 2017 Sep; 24(9):2632-2638. PubMed ID: 28560600
[TBL] [Abstract][Full Text] [Related]
56. Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer.
Lu JY; Xiao Y; Qiu HZ; Wu B; Lin GL; Xu L; Zhang GN; Hu K
J Surg Oncol; 2013 Sep; 108(4):213-9. PubMed ID: 23913795
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.
Tokuhara K; Ueyama Y; Nakatani K; Yoshioka K; Kon M
World J Surg Oncol; 2016 Apr; 14():136. PubMed ID: 27129578
[TBL] [Abstract][Full Text] [Related]
58. Oncologic Outcomes according to the Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradiation for Rectal Cancer.
Lee SY; Kim CH; Kim YJ; Kim HR
Oncology; 2015; 89(6):311-8. PubMed ID: 26426305
[TBL] [Abstract][Full Text] [Related]
59. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy.
Rogers AC; Gibbons D; Hanly AM; Hyland JM; O'Connell PR; Winter DC; Sheahan K
Mod Pathol; 2014 Jan; 27(1):156-62. PubMed ID: 23887296
[TBL] [Abstract][Full Text] [Related]
60. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer.
Layman RM; Thomas DG; Griffith KA; Smerage JB; Helvie MA; Roubidoux MA; Diehl KM; Newman LA; Sabel MS; Hayman JA; Pierce LJ; Hayes DF; Schott AF
Clin Cancer Res; 2007 Jul; 13(14):4092-7. PubMed ID: 17634534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
